Can Social Identity Equilibrium Moderate Alternative Equilibria? Repatriation in the Multinational Corporation
In: INTMAN-D-23-00392
26 Ergebnisse
Sortierung:
In: INTMAN-D-23-00392
SSRN
In: Defence Technology, Band 19, S. 63-75
ISSN: 2214-9147
In: Defence Technology, Band 18, Heft 9, S. 1643-1652
ISSN: 2214-9147
In: Defence Technology, Band 18, Heft 4, S. 547-556
ISSN: 2214-9147
In: Waste management: international journal of integrated waste management, science and technology, Band 30, Heft 7, S. 1206-1211
ISSN: 1879-2456
In: Waste management: international journal of integrated waste management, science and technology, Band 29, Heft 2, S. 792-796
ISSN: 1879-2456
Portals are the transition spaces between paths and places in an urban environment such as the entrance to a square from a connecting street. This paper aims to explore different forms of portals by considering their relationship with places. In doing so, a people-generated image analysis was adopted for two case studies conducted in popular Chinese recreational venues: Sanlitun Village, Beijing; and Xintiandi, Shanghai. Through an analysis of nearly 53,000 Instagram photographs, three different roles that a portal can fulfil are identified and defined as the 'doorway', the 'showroom', and the 'place'. These typologies are derived from a deeper understanding of urban space through the 'eyes of the users', and this knowledge can in turn influence the design process for the public realm and urban spaces.
BASE
In: Computers and Electronics in Agriculture, Band 122, S. 103-111
In: Defence Technology, Band 18, Heft 8, S. 1405-1415
ISSN: 2214-9147
In: Environmental science and pollution research: ESPR, Band 26, Heft 18, S. 18615-18623
ISSN: 1614-7499
Purpose: Calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are new agents approved by the US Food and Drug Administration for preventive treatment of chronic migraine. Comparison between CGRPmAbs and previously approved Botulinum neurotoxin A (BoNT-A) will inform optimal preventive treatment of chronic migraine, but head-to-head trials are lacking. We therefore aimed to perform adjusted indirect comparison between CGRPmAbs and BoNT-A through a meta-analysis. Methods: OVID MEDLINE, EMBASE and the Cochrane central register of controlled trials, clinical registries, and government websites were searched from inception to September 2019. Randomized controlled trials comparing CGRPmAbs or BoNT-A with placebo in the preventive treatment of chronic migraine were included. The primary outcomes were headache days and migraine days measured at week 12. Data were synthesized by using a frequentist approach; and the treatments were ranked by P-score. Results: We included 10 trials (n = 4,678) after screening 1049 candidates. Six trials were with low risk of bias. Fremanezumab had an effect similar to BoNT-A in the reduction of headache days at week 12 (standard mean difference [SMD] 0.08, 95%CI -0.55 to -0.7). Galcanezumab reduced more migraine days than BoNT-A at week 12 (SMD, -0.94, 95%CI −1.24 to −0.63); fremanezumab showed similar findings (SMD, −0.55, 95%CI −0.85 to −0.24). Galcanezumab and fremanezumab had better effect in mitigating headache impact at week 12. CGRPmAbs and BoNT-A had similar adverse event rate. Conclusion: CGRPmAbs and BoNT-A had similar effect in the preventive treatment of chronic migraine. BoNT-A might be preferentially selected owing to its cost-effectiveness profiles. Further studies with direct comparison of the two treatments are warranted.
BASE
In: Environmental science and pollution research: ESPR, Band 30, Heft 14, S. 41820-41833
ISSN: 1614-7499
In: Environmental science and pollution research: ESPR, Band 26, Heft 2, S. 1595-1605
ISSN: 1614-7499
In: info:eu-repo/semantics/altIdentifier/doi/10.2147/OTT.S109415
You-cai Zhu,1,2,* Chun-wei Xu,3,* Xiao-qian Ye,4 Man-xiang Yin,4 Jin-xian Zhang,2 Kai-qi Du,2 Zhi-hao Zhang,2 Jian Hu1 1Department of Thoracic Surgery, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, 2Department of Thoracic Surgery, Chinese People's Armed Police Force, Zhejiang Corps Hospital, Jiaxing, Zhejiang, 3Department of Pathology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 4Department of Pathology, Chinese People's Armed Police Force, Zhejiang Corps Hospital, Jiaxing, Zhejiang, People's Republic of China *These authors contributed equally to this work Abstract: ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation. Keywords: non-small cell lung cancer, EGFR gene mutation, ROS1 fusion gene
BASE
In: Ecotoxicology and environmental safety: EES ; official journal of the International Society of Ecotoxicology and Environmental safety, Band 144, S. 578-584
ISSN: 1090-2414